Andere Kunden interessierten sich auch für
![ADENOCARCINOMA PROSTATICO METASTATICO RESISTENTE ALLA CASTRAZIONE]( "ADENOCARCINOMA PROSTATICO METASTATICO RESISTENTE ALLA CASTRAZIONE")
ADENOCARCINOMA PROSTATICO METASTATICO RESISTENTE ALLA CASTRAZIONE26,99 €![ADENOCARCINOMA DA PRÓSTATA RESISTENTE À CASTRAÇÃO METASTÁTICA]( "ADENOCARCINOMA DA PRÓSTATA RESISTENTE À CASTRAÇÃO METASTÁTICA")
ADENOCARCINOMA DA PRÓSTATA RESISTENTE À CASTRAÇÃO METASTÁTICA26,99 €![Adenocarcinoma de Próstata Metastásico Resistente a Castración]( "Adenocarcinoma de Próstata Metastásico Resistente a Castración")
Adenocarcinoma de Próstata Metastásico Resistente a Castración26,99 €![ADÉNOCARCINOME MÉTASTATIQUE DE LA PROSTATE RÉSISTANT À LA CASTRATION]( "ADÉNOCARCINOME MÉTASTATIQUE DE LA PROSTATE RÉSISTANT À LA CASTRATION")
ADÉNOCARCINOME MÉTASTATIQUE DE LA PROSTATE RÉSISTANT À LA CASTRATION26,99 €![La castration chirurgicale dans le traitement du cancer de la prostate]( "La castration chirurgicale dans le traitement du cancer de la prostate")
La castration chirurgicale dans le traitement du cancer de la prostate39,99 €![Adenocarcinoma of the esophagogastric junction]( "Adenocarcinoma of the esophagogastric junction")
Adenocarcinoma of the esophagogastric junction26,99 €![HIV/TB-MR patients on a short course of multidrug-resistant tuberculosis]( "HIV/TB-MR patients on a short course of multidrug-resistant tuberculosis")
HIV/TB-MR patients on a short course of multidrug-resistant tuberculosis26,99 €
The initial treatments for localized prostate cancer, with a curative intent, are radical prostatectomy or radiation. However, these options cannot be applied to cases with locally advanced or metastatic disease. Objective: To characterize patients with metastatic prostate adenocarcinoma resistant to castration, treated with the chemotherapy regimen Docetaxel plus prednisone at the National Institute of Oncology and Radiobiology in the period 2008-2015.Material and Method:A quantitative, descriptive, retrospective non-experimental study was conducted to determine the characteristics of patients with metastatic castration-resistant prostate adenocarcinoma treated with the Docetaxel plus prednisone chemotherapy regimen.Results:A total of 40 patients were studied of which 50% were 60 and 69 years old and 30% 70 and 79 years old, with the mean age of presentation of CRPC being 67.3 years. 100% of the patients were in stage IV because of distant metastasis.